An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma

Obinutuzumab is a type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity better than rituximab. Given promising results with lenalidomide and rituximab, this phase 1b study assessed the safety and efficacy of lenalidomide combined with obinutuzumab (GALEN). Pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Morschhauser, Franck, Salles, Gilles, Le Gouill, Steven, Tilly, Herve, Thieblemont, Catherine, Bouabdallah, Krimo, Fabiani, Bettina, Ménard, Cédric, Tarte, Karin, Cartron, Guillaume, Houot, Roch
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6225348/
https://ncbi.nlm.nih.gov/pubmed/30068505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-853499
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados